Effect of Salovum® on Pressure, Oxygen and Inflammation in Glioblastoma
Recruiting
Phase 2
Interventional Study
Glioblastoma
No Placebo Group
Every participant receives an active treatment — no one gets a placebo.
Prior Safety Data
This treatment has already been tested in at least one earlier human trial.
At a Glance
- Age
- 18 – 75
- Sex
- Any
- Trial phase
- Phase 2
- Study type
- Interventional
- Purpose
- Treatment
- Participants needed
- 10 (estimated)
- Sponsor
- Peter Siesjö · Other
Think this trial could be right for you?
Answer a few quick questions to see if you may meet the eligibility requirements.
Check Your Eligibility
About This Trial
The objective of this clinical trial is to investigate the effects of Salovum®, an egg yolk powder enriched with the endogenous protein antisecretory factor, in participants undergoing diagnostic biopsies for suspected glioblastoma. The primary questions the trial seeks to answer are:
* Will Salovum® reduce intratumoral pressure?
* Will Salovum® influence the release of inflammatory cytokines fro…
Trial Locations
Loading…
Loading trial locations…
Eligibility Criteria
Inclusion Criteria:
1. Suspected glioblastoma
2. Age 18-75 years
3. Planned diagnostic biopsy
4. Informed consent of subject
Exclusion Criteria:
1\. Known egg yolk allergy
Contacts